Search over 3,000 reports

    Sarcopenia - Market Insights, Epidemiology and Market Forecast -2023-7 MM

    Sarcopenia - Market Insights, Epidemiology and Market Forecast -2023-7 MM
    Date: Nov, 2017
    Type: Pharmaceutical Industry Report
    Pages: 51
    Geography: Global
    Delivery Timeline: 24 Hours
    SKU: DIMI0004
    DelveInsight's "Sarcopenia - Market Insights, Epidemiology and Market Forecast-2023-7 MM" Report provides an overview of the disease and global market size of the Sarcopenia for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the prevalent cases of Sarcopenia from 2013-2023.
    Sarcopenia is the progressive loss of skeletal muscle that comes with aging. Sarcopenia is multifactorial in cause. Most people begin to lose modest amounts of muscle mass after age 30, but the resulting loss of strength increases exponentially with age. Of the contributory factors relating to the development of sarcopenia inadequate protein intake, increased splanchnic extraction of amino acids, decreased muscular response to postprandial anabolic stimuli and vitamin D deficiency are directly related to nutrition.
    According to DelveInsight, the market size of Sarcopenia in 7 MM is estimated to be USD XX Million by 2023 at a CAGR of 2.36% for the forecast period i.e., 2013-2023. Also the prevalence cases in 7 MM are expected to increase and reach up to 42,969,489 cases by year 2023.
    The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
    Scope
    The report will help in developing business strategies by understanding the trends shaping and driving the Sarcopenia market.
    Organize sales and marketing efforts by identifying the best opportunities for Sarcopenia in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
    To understand the future market competition in the 7MM market of Sarcopenia and Insightful review of the key market drivers and barriers.
    To understand the regulatory scenario in major markets.

    The Report also covers the detailed historical and forecasted Sarcopenia market covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023.
    Report Introduction
    Sarcopenia: Overview
    Introduction
    Pathophysiology
    Symptoms
    Diagnosis
    Sarcopenia categories and stages
    EWGSOP Conceptual Stages of Sarcopenia
    Treatment
    Challenges
    Unmet Need
    Epidemiology of Sarcopenia in 7MM
    Epidemiology and Patient Population
    Assumptions and Caveats
    Prevalent Population of Sarcopenia in 7MM
    United States
    Europe
    United Kingdom
    France
    Italy
    Spain
    Germany
    Japan
    Pipeline Drugs in Development
    Enobosarm: GTX, Inc.
    Product Description
    Clinical Development
    Advantages & Disadvantages
    Product Profile
    REGN-1033: Regeneron Pharmaceuticals
    Product Description
    Clinical Development
    Advantages & Disadvantages
    Product Profile
    LY-2495655: Eli Lilly and Company
    Product Description
    Clinical Development
    Advantages & Disadvantages
    Product Profile
    Testosterone Enanthate + Finasteride: Endo Pharmaceuticals
    Product Description
    Clinical Development
    Advantages & Disadvantages
    Product Profile
    BYM338: Novartis AG
    Product Description
    Clinical Development
    Advantages & Disadvantages
    Product Profile
    Sarconeos: Biophytis
    Product Description
    Clinical Development
    Advantages & Disadvantages
    Product Profile
    Global Market Scenario for Sarcopenia
    Sarcopenia: Country-Wise Market Analysis
    7 Major Market Size of Sarcopenia (2013-2023)
    Global Market Size by Geography
    United States
    Market size of Europe
    United Kingdom
    France
    Italy
    Spain
    Germany
    Japan
    Market Drivers and Market Barriers for Sarcopenia
    Future Prospects for Sarcopenia
    Appendix
    Report Methodology
    Consulting Services
    Disclaimer
    About DelveInsight

    Table 1: Prevalent Population of Sarcopenia in 7MM (2013-2023)
    Table 2: Prevalent Population of Sarcopenia in United States (2013-2023)
    Table 3: Prevalent Population of Sarcopenia in United Kingdom (2013-2023)
    Table 4: Prevalent Population of Sarcopenia in France (2013-2023)
    Table 5: Prevalent Population of Sarcopenia in Italy (2013-2023)
    Table 6: Prevalent Population of Sarcopenia in Spain (2013-2023)
    Table 7: Prevalent Population of Sarcopenia in Germany (2013-2023)
    Table 8: Prevalent Population of Sarcopenia in Japan (2013-2023)
    Table 9: Pipeline Drugs and Mechanism of Action, 2016
    Table 10: Total 7 Major Market size of Sarcopenia in USD Million (2013-2023)
    Table 11: United States Market Size of Sarcopenia in USD, Million (2013-2023)
    Table 12: United Kingdom Market Size of Sarcopenia in USD, Million (2013-2023)
    Table 13: France Market Size of Sarcopenia in USD, Million (2013-2023)
    Table 14: Italy Market Size of Sarcopenia in USD, Million (2013-2023)
    Table 15: Spain Market Size of Sarcopenia in USD, Million (2013-2023)
    Table 16: Germany Market Size of Sarcopenia in USD, Million (2013-2023)
    Table 17:Japan Market Size of Sarcopenia in USD, Million (2013-2023)
    Figure 1: Mechanisms of Sarcopenia
    Figure 2: EWGSOP Screening Algorithm
    Figure 3: Prevalent Population of Sarcopenia in 7MM (2013-2023)
    Figure 4: Prevalent Population of Sarcopenia in United States (2013-2023)
    Figure 5: Prevalent Population of Sarcopenia in United Kingdom (2013-2023)
    Figure 6: Prevalent Population of Sarcopenia in France (2013-2023)
    Figure 7: Prevalent Population of Sarcopenia in Italy (2013-2023)
    Figure 8: Prevalent Population of Sarcopenia in Spain (2013-2023)
    Figure 9:Prevalent Population of Sarcopenia in Germany (2013-2023)
    Figure 10:Prevalent Population of Sarcopenia in Japan (2013-2023)
    Figure 11: Total 7 Major Market Size of Sarcopenia in USD, Million (2013-2023)
    Figure 12: United States Market Size of Sarcopenia in USD, Million (2013-2023)
    Figure 13: United Kingdom Market Size of Sarcopenia in USD, Million (2013-2023)
    Figure 14: France Market Size of Sarcopenia in USD, Million (2013-2023)
    Figure 15: Italy Market Size of Sarcopenia in USD, Million (2013-2023)
    Figure 16: Spain Market Size of Sarcopenia in USD, Million (2013-2023)
    Figure 17: Germany Market Size of Sarcopenia in USD, Million (2013-2023)
    Figure 18:Japan Market Size of Sarcopenia in USD, Million (2013-2023)
    Sarcopenia Market (7MM)

    Sarcopenia Market forecasting

    Sarcopenia Sales forecasting

    Sarcopenia Market segments

    Sarcopenia Epidemiology

    Sarcopenia Pipeline products and technologies

    Sarcopenia Competitive landscape

    Sarcopenia SWOT analysis

    Sarcopenia Market Driver's and barriers

    Sarcopenia Key Companies and Funding

    • Single User License
      (20% Off)
      $4,950.00
      $3960
    • Site License
      (30% Off)
      $9,900.00
      $6930
    • Global License
      (40% Off)
      $14,850.00
      $8910

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap